PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
2.87
Current Ratio 1.25–1.5x Drug Manufacturers - Specialty & Generic median of 2.37. Mohnish Pabrai might suspect the market overlooks this liquidity advantage.
1.99
Quick Ratio 1.25–1.5x Drug Manufacturers - Specialty & Generic median of 1.73. Mohnish Pabrai might see the market underpricing this strong liquidity position.
1.48
Cash Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 0.82. Joel Greenblatt might see a strategic advantage in crisis periods.
15.56
Interest coverage of 15.56 versus zero Drug Manufacturers - Specialty & Generic median. Walter Schloss would verify if our debt service capacity provides advantages.
-0.24
Negative short-term coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize cash flow quality and look for immediate refinancing solutions.